CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
Paclitaxel Protein Bound (Abraxane)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03138720
NCT03138720Phase 2Completed
CompareCT.gov

A Phase II Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Paricalcitol as Pre-operative Treatment in Patients With Untreated Resectable, Borderline Resectable and Locally Advanced Adenocarcinoma of the Pancreas

HonorHealth Research Institute·interventional·Posted May 3, 2017·Updated Apr 22, 2026

In Brief

A Phase 2 clinical trial evaluating Paclitaxel Protein Bound (Abraxane) for Resectable Pancreatic Cancer and 3 related conditions. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The purpose of this study is to determine if the combination of paclitaxel protein bound, gemcitabine, cisplatin, paricalcitol are effective in individuals with resectable and unresectable pancreatic cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsResectable Pancreatic Cancer, Unresectable Pancreatic Cancer, Pancreatic Adenocarcinoma, Neoadjuvant Pancreatic Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMay 3, 2017
Enrollment StartMay 23, 2017
Primary CompletionJul 13, 2023
Study CompletionNov 3, 2025
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 9.2 years ago

Interventions

Paclitaxel Protein Bound (Abraxane)drug

Participants will be treated with the regimen prior to having surgery. Participants will complete 3 cycles (cycle is 21 days) and then will be evaluated for CA19-9 normalization. If CA19-9 is normalized, then participant will be scheduled for surgery and moved to standard of care. If CA19-9 is not normalized then participants will complete another 3 cycles.